2025-01-27 | Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting PDF Report Presentation Webcast
2024-12-23 | Ascelia Pharma Patent Granted in China for Second Generation Orviglance PDF Report Presentation Webcast
2024-12-17 | Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025 PDF Report Presentation Webcast
2024-12-02 | Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
2024-11-06 | Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE PDF Report Presentation Webcast
2024-10-24 | Ascelia Pharma Presents Late-Breaking Abstract on SPARKLE Data at the American Society of Nephrology Kidney Week Congress 2024 PDF Report Presentation Webcast
2024-09-30 | Ascelia Pharma Finalizes Rights Issue with Runway Extended to Late 2025 PDF Report Presentation Webcast
2024-05-07 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-04-18 | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility PDF Report Presentation Webcast
2024-04-10 | Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 PDF Report Presentation Webcast
2024-01-24 | Orviglance Review Article Published in Investigative Radiology PDF Report Presentation Webcast
2023-12-07 | Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024 PDF Report Presentation Webcast
Regulatory 2023-11-09 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
2023-10-04 | Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology PDF Report Presentation Webcast
2023-09-13 | Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding PDF Report Presentation Webcast
2023-08-09 | Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast